Related Experiment Video
Updated: Aug 7, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 19, 2013
Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death
1Department of Medicine and Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-Dong, Kangnam-Ku, Seoul, Korea.
Abstract:
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, induces growth arrest in a variety of cancer cell lines. Its mechanism of action, however, has not been completely elucidated. E2F-1 is thought to act as an oncogene and a tumour suppressor, with its action probably dependent upon the cellular context. We have shown in this study that transcriptional regulation and proteasomal degradation of E2F-1 are critical regulatory events in lovastatin-induced cell death. Accompanying this is a reduction in the E2F-1-regulated expression of cell cycle genes such as c-myc, cyclin D1, cyclin A and cyclin B1. Cell cycle analysis demonstrated that the accumulation of apoptotic cells was preceded by a progressive decrease in the S-phase cell population in response to lovastatin. Although expression of E2F-1 was reduced in three prostate cancer cell lines-PC-3, LNCaP and DU-145-the p21 and p27 protein levels were not increased in all the cell lines treated, suggesting that increase in p21 and p27 protein expression per se is not responsible for lovastatin-mediated down-regulation of E2F-1. The subsequent apoptotic death of these cells in the presence of lovastatin can be prevented by forced ectopic expression of E2F-1. Taken together, these facts imply that E2F-1 is the target of an HMG-CoA inhibitor and critical cell death mediator in prostate cancer cells.
Insights
Lovastatin, an HMG-CoA reductase inhibitor, triggers cancer cell death by regulating E2F-1. This study reveals E2F-1 as a critical mediator in lovastatin-induced apoptosis, particularly in prostate cancer cells.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Lovastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor known to induce cancer cell growth arrest.
- The precise mechanism of lovastatin's action, particularly its impact on E2F-1, remains incompletely understood.
- E2F-1's role as an oncogene or tumor suppressor is context-dependent.
Purpose of the Study:
- To elucidate the mechanism by which lovastatin induces cell death.
- To investigate the role of E2F-1 in lovastatin-mediated apoptosis in cancer cells.
- To determine if E2F-1 is a direct target of HMG-CoA reductase inhibitors in prostate cancer.
Main Methods:
- Investigated the transcriptional regulation and proteasomal degradation of E2F-1 in response to lovastatin.
- Analyzed the expression of E2F-1-regulated cell cycle genes (c-myc, cyclin D1, cyclin A, cyclin B1).
- Performed cell cycle analysis and assessed protein levels of p21 and p27.
- Utilized forced ectopic expression of E2F-1 to evaluate its role in preventing lovastatin-induced apoptosis.
Main Results:
- Lovastatin treatment led to transcriptional regulation and proteasomal degradation of E2F-1, critical for cell death.
- Expression of E2F-1-regulated genes, including c-myc and cyclins, was reduced.
- Cell cycle analysis showed a decrease in S-phase cells preceding apoptosis.
- While E2F-1 decreased in prostate cancer cell lines, p21 and p27 levels did not consistently increase.
- Forced expression of E2F-1 rescued cells from lovastatin-induced apoptosis.
Conclusions:
- E2F-1 is a key mediator of lovastatin-induced apoptotic cell death in prostate cancer.
- Lovastatin targets E2F-1 through transcriptional and post-translational mechanisms.
- E2F-1 down-regulation is essential for lovastatin's cytotoxic effects in these cancer models.
